No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Ornithine Transcarbamylase Deficiency (OTCD) is a rare genetic disorder that affects the body's ability to break down proteins. It is caused by a deficiency of the enzyme ornithine transcarbamylase (OTC). Treatment for OTCD typically involves dietary modifications, medications, and enzyme replacement therapy. Hematological drugs are used to treat OTCD, as they can help to reduce the symptoms of the disorder. These drugs can help to reduce the amount of ammonia in the blood, as well as reduce the risk of complications such as seizures and coma.
The OTCD drug market is a niche market, with a limited number of companies offering treatments. These companies are focused on developing treatments that are safe and effective for patients with OTCD. Some of the companies in the OTCD drug market include Genzyme Corporation, Shire Pharmaceuticals, and BioMarin Pharmaceuticals. Show Less Read more
